(D’Addio et al., 2013) Abatacept (CTLA-4–Ig fusion protein), a costimulatory inhibitor that targets CD80, induced partial or CR of proteinuria in patients with FSGS (Yu et al., 2013; Trimarchi, 2015), in which CD80 seemed to be minimally expressed in glomeruli and urine (Garin et al., 2010). This evidence concerns the gene CD80 and focal segmental glomerulosclerosis.